Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Real-time Estimate Cboe BZX Other stock markets 02:04:29 2024-04-29 pm EDT			5-day change	1st Jan Change
1.415 ^USD	-1.74%		-6.62%	-48.16%

Apr. 23	CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	CI
Feb. 14	CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Appoints Mario Gobbo to Its Board of Directors	Apr. 23	BU
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	Mar. 19	BU
CEL-SCI Corporation Issues Letter to Shareholders	Mar. 06	BU
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	Feb. 15	BU
Cel-Sci: Fiscal Q1 Earnings Snapshot	Feb. 14	AQ
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock	Feb. 13	BU
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	Feb. 12	AQ
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	Feb. 09	BU
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head and Neck Cancer Drug	Feb. 07	AQ
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	Feb. 06	BU
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path towards Marketing Authorization for Multikine	Feb. 01	AQ
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®	Jan. 31	BU
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments	Dec. 22	BU
UK'S National Institute for Health and Care Excellence Selects CEL-SCI's Multikine as Potential New Standard of Care for Head and Neck Cancer	Dec. 05	AQ
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer	Dec. 04	BU
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock	Nov. 20	BU
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock	Nov. 16	BU
CEL-SCI Issues Letter to Shareholders	23-10-30	BU
CEL-SCI Releases Video Detailing Recent Phase 3 Findings and its Plans to Seek Immediate Regulatory Approvals	23-10-25	AQ
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals	23-10-24	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Press Releases

Filters